Inventia Healthcare Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Inventia Healthcare Limited Pharmaceutical Export Portfolio Dataset — 11 Products, $36.5M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Inventia Healthcare Limited — Pharmaceutical Exporter Profile (2026) | 11 Products, $36.5M Trade | TransData Nexus

Inventia Healthcare Limited

Indian Pharmaceutical Exporter · Diabetes & Endocrine Specialist · $36.5M Total Trade · DGFT Verified

Inventia Healthcare Limited is an Indian pharmaceutical exporter with a total trade value of $36.5M across 11 products in 6 therapeutic categories. Based on 1,098 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Metformin ($16.4M), Telmisartan ($5.3M), Dapagliflozin ($4.6M).

Inventia Healthcare Limited — Export Portfolio & Destination Treemap

Inventia Healthcare Limited pharmaceutical export portfolio — 11 products across 6 therapeutic categories. Source: Indian Customs (DGFT).

Who is Inventia Healthcare Limited? — Company Overview & Market Position

Inventia Healthcare Limited, established on September 27, 1985, is a privately held pharmaceutical development and manufacturing company headquartered in Mumbai, Maharashtra, India. The company's Corporate Identification Number (CIN) is U24239MH1985PLC037597. As of August 7, 2025, Inventia Healthcare reported an annual revenue of $89.42 million USD, with a net profit of $6.04 million USD for the fiscal year ending March 31, 2024. The company employs approximately 962 individuals, reflecting its substantial presence in the pharmaceutical sector. In August 2024, Platinum Equity acquired a controlling stake in Inventia Healthcare, indicating a strategic move to enhance the company's growth and market reach.

What Does Inventia Healthcare Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Metformin$16.4M 2Telmisartan$5.3M

Product Portfolio — Top 11 by Export Value

Inventia Healthcare Limited exports 11 pharmaceutical products across 6 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Metformin	Diabetes & Endocrine	$16.4M	329	3.5%	3
2	Telmisartan	Cardiovascular	$5.3M	197	0.0%	9
3	Dapagliflozin	Advanced Diabetes Medications	$4.6M	111	9.3%	4
4	Glimepiride	Diabetes & Endocrine	$3.0M	108	3.9%	4
5	Gliclazide	Advanced Diabetes Medications	$2.0M	134	0.7%	13
6	Lansoprazole	Gastrointestinal	$1.9M	55	0.6%	13
7	Fenofibrate	Lipid & Metabolism	$1.4M	60	2.0%	12
8	Nitrofurantoin	Advanced Antibiotics	$600.0K	12	1.8%	3
9	Diltiazem	Cardiovascular	$504.2K	36	2.8%	12
10	Domperidone	Gastrointestinal	$419.2K	36	1.4%	11
11	Isosorbide	Cardiovascular	$393.5K	20	0.9%	11

Inventia Healthcare Limited exports 11 pharmaceutical products across 6 therapeutic categories with a total export value of $36.5M. The top category is Diabetes & Endocrine (53.2% of portfolio), followed by Advanced Diabetes Medications (18.0%), indicating a concentrated portfolio with the top 5 products accounting for 85.7% of total export value.

Inventia Healthcare Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Inventia Healthcare operates a state-of-the-art manufacturing facility located in Ambernath, Maharashtra, India. This facility specializes in the production of oral solid dosage (OSD) forms, including tablets and capsules, catering to both regular and value-added generics. The manufacturing platform is accredited by stringent regulatory authorities such as the U.S. FDA and the U.K. MHRA, ensuring compliance with international quality standards. Additionally, the company maintains a research and development center in Thane, Maharashtra, focusing on the development of complex generic and novel pharmaceutical products.

3Key Leadership

The leadership team at Inventia Healthcare is headed by Co-Founder, Chairman, and Managing Director Janak Shah, who has been instrumental in the company's growth and strategic direction. Naresh Shah serves as the Chief Operating Officer, overseeing the company's operational activities. In August 2024, Platinum Equity acquired a controlling stake in Inventia Healthcare, indicating a strategic move to enhance the company's growth and market reach.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Inventia Healthcare Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Inventia Healthcare has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, and Australia. The company's manufacturing facility in Ambernath is accredited by the U.S. FDA and the U.K. MHRA, ensuring compliance with stringent regulatory standards. This accreditation facilitates the company's ability to supply pharmaceutical products to these markets. Additionally, Inventia Healthcare has been involved in filing Abbreviated New Drug Applications (ANDAs) with the U.S. FDA, indicating its commitment to expanding its product portfolio in the U.S. market.

2Emerging Markets

Inventia Healthcare has expanded its reach to emerging markets, including Africa, Latin America, and Southeast Asia. The company's manufacturing facility holds various regulatory approvals, such as those from the U.S. FDA, U.K. MHRA, KFDA, ANVISA, INVIMA, COFEPRIS, and others, enabling access to these regions. This global footprint allows Inventia Healthcare to cater to a diverse customer base and meet the pharmaceutical needs of various emerging markets.

3Geographic Strategy

Inventia Healthcare Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Inventia Healthcare's manufacturing facility in Ambernath, Maharashtra, India, is accredited by the U.S. FDA, ensuring compliance with stringent regulatory standards. This accreditation facilitates the company's ability to supply pharmaceutical products to the U.S. market. Additionally, Inventia Healthcare has been involved in filing Abbreviated New Drug Applications (ANDAs) with the U.S. FDA, indicating its commitment to expanding its product portfolio in the U.S. market.

2WHO & EU GMP

Inventia Healthcare's manufacturing facility holds various regulatory approvals, including those from the U.S. FDA and the U.K. MHRA. While specific details regarding WHO prequalification and EU GMP certificates are not explicitly mentioned in the available sources, the company's adherence to international quality standards suggests a commitment to meeting global regulatory requirements.

3CDSCO & Indian Regulatory

Inventia Healthcare operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company's manufacturing facility in Ambernath is accredited by the U.S. FDA and the U.K. MHRA, indicating compliance with international standards. Specific details regarding CDSCO manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) are not explicitly mentioned in the available sources.

Inventia Healthcare Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Inventia Healthcare operates in a competitive landscape, supplying both semi-finished and finished oral solid dosage (OSD) formulations for regular and value-added generics. The company's partners include global and leading local pharmaceutical companies that sell in more than 40 countries across North America, South America, Europe, Southeast Asia, the Middle East, and Africa. While specific market share data is not available, Inventia Healthcare's extensive global reach and regulatory accreditations position it as a significant player in the pharmaceutical manufacturing sector.

2Key Differentiators

Inventia Healthcare's key differentiators include its state-of-the-art manufacturing facility in Ambernath, Maharashtra, which is accredited by the U.S. FDA and the U.K. MHRA, ensuring compliance with stringent regulatory standards. The company's focus on developing complex generic and novel pharmaceutical products enhances its product portfolio and supports patient compliance and comfort. Additionally, Inventia Healthcare's expansion into over 50 countries globally demonstrates its ability to cater to diverse markets and meet various pharmaceutical needs.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Inventia Healthcare Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Inventia Healthcare has demonstrated a strong track record in pharmaceutical manufacturing, with a total export value of $36.5 million USD and 1,098 shipments across 11 products in 2022-2026. The company's portfolio concentration, with the top five products accounting for 85.7% of exports, indicates a focused approach to product development and market penetration. The absence of publicly available records indicating any Form 483 observations, warning letters, or import alerts suggests a reliable and compliant manufacturing process. These factors collectively position Inventia Healthcare as a dependable supplier in the pharmaceutical industry.

2Certifications to Verify

Importers should verify the following certifications to ensure compliance and quality standards:

FDA Approval: Confirm that the manufacturing facility is registered with the U.S. FDA. This can be verified through the FDA's official website or by contacting the FDA directly.

WHO-GMP Certification: Check for World Health Organization Good Manufacturing Practice certification. Verification can be done by consulting the WHO's official website or contacting the organization.

Frequently Asked Questions — Inventia Healthcare Limited

How many pharmaceutical products does Inventia Healthcare Limited export from India?

Inventia Healthcare Limited exports 11 pharmaceutical products across 6 therapeutic categories. The top exports are Metformin ($16.4M), Telmisartan ($5.3M), Dapagliflozin ($4.6M), Glimepiride ($3.0M), Gliclazide ($2.0M). Total export value is $36.5M.

What is Inventia Healthcare Limited's total pharmaceutical export value?

Inventia Healthcare Limited's total pharmaceutical export value is $36.5M, based on 1,098 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Inventia Healthcare Limited cover?

Inventia Healthcare Limited exports across 6 therapeutic categories. The largest are Diabetes & Endocrine (53.2%, 2 products), Advanced Diabetes Medications (18.0%, 2 products), Cardiovascular (16.9%, 3 products).

Get Full Inventia Healthcare Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.